We are pleased to inform you that ASKLEP Inc. will be moving its Headquarters to a new location on April 25th, 2011. As the company continues to grow, it is necessary for us to acquire additional office space in Tokyo. Our current space in Akihabara will serve as a branch office. We do not anticipate any disruption of business during the move.

Please note this change of address and phone number for future correspondence with us. We apologize for any inconvenience this may cause but we look forward to better serving you from our new premises.

April, 2011
Takenori Ogawa
President and Representative Director
ASKLEP Inc.

Special Guests from the State Food and Drug Administration (SFDA) China, a Chinese clinical trial investigator, and Japanese Pharma presented at the event. ”Quality and Speed of clinical development from SFDA Biostatistical stand point”, “Clinical development in China, from an investigator stand point”, and “Chinese clinical development Strategy and its influence”, and “Points of Chinese Clinical Trails & Quality in China (Auditor’s point of view)”. The conference included the latest information and some case studies, and received high praise from attendees mentioning that the conference is very useful when they conduct clinical trials in China.

ASKLEP has taken the lead role among Japanese CROs in providing these events to further add value and support to clients beyond the borders of Japan.

ASKLEP will continue to be the “Gateway to CRO Services for Asian and Global Clinical Trials”.

About ASKLEP
Asklep, Inc., (http://www.asklep.co.jp) founded in 1992, in Tokyo, Japan, provides clinical research services in monitoring, data management, biostatistics, regulatory & consulting, CRA training, etc. ASKLEP is an INTAGE Group Company. INTAGE, INC., (http://www.intage.co.jp) is the largest marketing research company in Japan and the eleventh largest globally. It has one of the most comprehensive healthcare solution services in the industry

Contact: ASKLEP Corporate Planning and Development Dept. Tel: 81-3-5294-5223

With the globalization of clinical development, ASKLEP has already executed strategic partnership agreements with CROs in Europe, North America, Taiwan, and Korea. In particular, ASKLEP sees the Asian territory as a high growth region for clinical development and has been actively developing services and geographic coverage to meet those needs.. .

Growth for China in the pharmaceutical industry is expected to exceed two trillion yen, and China’s participation in Asian clinical trials is also expected to grow dramatically. In June 2010, ASKLEP established a representative office in Shanghai, China as a base of operations for conducting clinical trials in China.

By establishing a local subsidiary, ASKLEP aims to acquire market share in China’s developing clinical market and to include Japan in studies being conducted in China. ASKLEP’s goal is to expand its business by utilizing local networks and local management expertise. This follows our concept of “Think Global Act Local”.

ASKELP expects multi-national and Japanese pharmaceutical and device companies to continue increasing trial activities in China. We plan to be there not only to support these clients, but also local Chinese pharmaceutical companies as well.

About ASKLEP China
Company name: ASKLEP CHINA Inc.
Headquarters: Huangpu, Shanghai China
Capital: $500,000 USD (ASKLEP: 100%)
Representatives: Chairman Yuichi Yahagi
Director and General Manager Hozui Imatsu 
Start of Operations: December 1, 2010 (projecting)

About Asklep
Asklep, Inc., (www.asklep.co.jp) founded in 1992, in Tokyo, Japan, provides clinical research services in monitoring, data management, biostatistics, CRA training, and others. ASKLEP Inc. is an INTAGE Group Company (www.intage.co.jp), and utilizes its medical research function, and system expertise to provide total solution services to our clients.

About INTAGE
INTAGE Inc., (http://www.intage.co.jp/english/) listed on the 1st Section of the Tokyo Stock Exchange, was founded in 1960, in Tokyo, Japan. The INTAGE Group has been a pioneer and is the leader in the field of marketing research in Japan. We create globally unique and innovative business models that combine marketing know-how with IT solutions.

For further information please contact
ASKLEP Inc. Corporate Planning and Development
Contact Person: Yuichi Yahagi
Phone: +81-3-5294-5222 Fax: +81-3-5294-5231
Inquires by mail：http://www.asklep.co.jp/english/contact/

INTAGE Inc. PR・IR Group
Contact Person: Suzuki/ Uemura
Phone: +81-3-5294-6000 Fax: +81-3-5294-8318
Phone: +81-3-5294-5222 
Inquires by mail：http://www.intage.co.jp/english/contact/

ASKLEP, a full-service CRO with headquarters in Tokyo and Representative Office in Shanghai China, will exhibit together with their global strategic partners, Harrison Clinical Research (Europe), ASKA Research (Canada), Qualitix Clinical Research (Taiwan) and DreamCIS (Korea). ASKLEP is pleased to continue its participation in this event and this will be the 4th year we have participated in this event.

ASKLEP and Partners welcome attendees to drop by their booths to visit and discuss any clinical research and consulting needs in the Asia region.

Visitors can find ASKLEP at booth #1326, with all partners near by. We look forward to seeing with you there.

About Asklep
Asklep, Inc., (http://www.asklep.co.jp) founded in 1992, in Tokyo, Japan, provides clinical research services in monitoring, data management, biostatistics, regulatory & consulting, CRA training, etc. June 2010, ASKLEP opened its first overseas representative office in Shanghai, China. ASKLEP is an INTAGE Group Company. INTAGE, INC., (www.intage.co.jp) is the largest marketing research company in Japan and the eleventh largest globally. It has one of the most comprehensive healthcare solution services in the industry.

While clinical research development is growing at lightening speed in the Asia region, ASKLEP is on the ground in this vital market, to provide clients with in-depth consulting services for market and drug information in the clinical development arena. ASKLEP has already executed strategic partnership agreements with a Taiwan CRO, Qualitix Clinical Research and with a Korean CRO, DreamCIS Inc.Through these alliances, ASKLEP has established a structure where they can conduct and manage trials in East Asia among these three countries. By adding Shanghai Representative Office in China, ASKLEP has accelerated and expanded beyond these territories by moving into mainland China. This reinforces ASKLEP’s commitment to providing clients with a full spectrum of services and greater geographic coverage.

Corporate Profile
Company Name: ASKLEP Inc. Shanghai Representative Office
Address: The Exchange-SOHO16F　No.1486, Nanjing Road West, Jing’an District, Shanghai, China
Establishment: June 2, 2010

About Asklep
Asklep, Inc., (www.asklep.co.jp) founded in 1992, in Tokyo, Japan, provides clinical research services in monitoring, data management, biostatistics, regulatory & consulting, CRA training, etc. ASKLEP is an INTAGE Group Company. INTAGE, INC., (www.intage.co.jp) is the largest marketing research company in Japan and the eleventh largest globally. It has one of the most comprehensive healthcare solution services in the industry.

For further information please contact
ASKLEP Inc. Corporate Planning and Development
INTAGE Akihabara Bldg., 3 Kanda Neribei-cho Chiyoda-ku, Tokyo 101-8202 Japan
Phone: +81-3-5294-5222 
Inquires by mail：https://www.asklep.co.jp/en/inquiry/

ASKLEP’s regional CRO partners and guests from Japanese Pharma participated as speakers for the event. Partners from Taiwan and Korea presented on “regulatory changes and what we need to know”, and guest speakers from their perspective as Japanese Pharma, presented on the “current situation and trends in clinical development in China”. The conference included the latest information and some case studies, and received high praise from attendees mentioning that the conference is very useful when they conduct Asian Clinical Trials.

ASKLEP has taken the lead role as a Japanese CRO in providing these types of events to further add value and support clients beyond the borders of Japan.

ASKLEP will continue to be the “Gateway to CRO Services for Asian and Global Clinical Trials”, and keep meeting client needs.

About ASKLEP
Asklep, Inc., (http://www.asklep.co.jp) founded in 1992, in Tokyo, Japan, provides clinical research services in monitoring, data management, biostatistics, regulatory & consulting, CRA training, etc. ASKLEP is an INTAGE Group Company. INTAGE, INC., (http://www.intage.co.jp) is the largest marketing research company in Japan and the eleventh largest globally. It has one of the most comprehensive healthcare solution services in the industry.

Contact: ASKLEP Corporate Planning and Development Dept. Tel: 81-3-5294-5223

The globalization of clinical development has been advancing rapidly and Asia, on a regional basis, is no exception. ASKLEP recognized this early and began establishing a network of CROs in Asia. The focus for this conference is to provide insight and the latest in regulatory changes in strategic markets for clinical development, Taiwan and Korea. There will also be other topics covered and is geared toward Research and Development professionals at biotech, pharmaceutical and device manufacturers.

The conference will feature speakers from ASKLEP’s regional CRO Asia network, and we will also have guest speakers from Pharmaceutical industry participating.

Conference Information (http://www.asklep.co.jp/conference/)
Date: February 17th, 2010
Time: 14:00 – 18:00 (18:15- Reception)
Place: Tokyo International Forum (Yurakucho) B-Block 5th Floor 
http://www.t-i-forum.co.jp/english/index.html

About ASKLEP
Asklep, Inc., (http://www.asklep.co.jp) founded in 1992, in Tokyo, Japan, provides clinical research services in monitoring, data management, biostatistics, regulatory & consulting, CRA training, etc. ASKLEP is an INTAGE Group Company. INTAGE, INC., (http://www.intage.co.jp) is the largest marketing research company in Japan and the eleventh largest globally. It has one of the most comprehensive healthcare solution services in the industry

About Qualitix Clinical Research
Qualitix Clinical Research Co., Ltd. (http://www.qualitix.com.tw/) Qualitix is a full service CRO based in Taiwan and focuses on clinical monitoring and site management services for multinational phase II and phase III studies. Qualitix was established in June 2008; however, CRO business was commenced since 1997 under its parent company Genovate Biotechnology Co., Ltd. This year, Qualitix has established its presence in China and expanding its service area to China.

About Dream CIS
With abundant experience and know-how, DreamCIS (http://www.dreamcis.com) helps pharmaceutical, biotech and device manufacturers plan and manage trials from beginning to end. DreamCIS strengths are study consulting and study design, medical writing and feasibility for patient recruitment along with subsequent clinical monitoring. DreamCIS provides clinical trial services, either for an entire project or certain stages of a project, that meet client needs, in accordance with KGCP, GCP and ICH guidelines. Since the company established in 2000, DreamCIS has conducted 255 clinical trials in Phase I to IV, and over 480 projects in Pharmacovigilance and Post-Marketing Surveillance.

Contact: ASKLEP Corporate Planning and Development Dept. Tel: 81-3-5294-5223

Harrison Clinical Research (Europe), ASKA Research (Canada), DreamCIS (Korea) and Qualitix Clinical Research (Taiwan) are ASKLEP’s global CRO partners along with XClinical, an EDC provider. Our network of CROs allows our clients access to strategic markets around the globe where our partners provide quality CRO services.

To learn more about us and our global partners, we welcome you to drop by our booth in the exhibition area anytime. A representative from Harrison Clinical Research will be in attendance to answer any questions.

The 6th Annual Japan DIA Meeting
TowerHallFunabori(Tokyo, Japan)　＜MAP＞
October 22－23, 2009

ASKLEP Booth ＃8

About ASKLEP
Asklep, Inc., (http://www.asklep.co.jp) founded in 1992, in Tokyo, Japan, provides clinical research services in monitoring, data management, biostatistics, regulatory & consulting, CRA training, etc. ASKLEP with over 300 professionals located in Tokyo and Osaka, offers high quality clinical research services to pharmaceutical, biotech and device companies. ASKLEP is an INTAGE Group Company (www.intage.co.jp)

About Harrison Clinical Research Group
Harrison Clinical Research Group (http://www.harrisonclinical.com/), is a Munich, Germany based CRO with 11 offices throughout Europe, and a state-of-the-art Phase I facility in Munich. Harrison offers the full-range of services required for the clinical development and registration of new pharmaceutical products and medical devices, from single studies to complete development programs. The international project management and monitoring teams perform Phase I – IV studies either locally or globally, as required. HCR was established in 1987 and is ISO9001:2000 compliant.

About ASKA Research
ASKA Research (http://www.askaresearch.com/), is a Vancouver, Canada based CRO who manage and monitor all facets of regional, national and North American clinical trials. ASKA Research provides a full range of multi-center clinical trial management and monitoring services from project conception to marketing approval. ASKA Research, a Division of Valerie Willetts & Associates Inc., was founded in 1995.

About Dream CIS
With abundant experience and know-how, DreamCIS (www.dreamcis.com) helps pharmaceutical, biotech and device manufacturers plan and manage trials from beginning to end. DreamCIS strengths are study consulting and study design, medical writing and feasibility for patient recruitment along with subsequent clinical monitoring. DreamCIS provides clinical trial services, either for an entire project or certain stages of a project, that meet client needs, in accordance with KGCP, GCP and ICH guidelines. Since the company established in 2000, DreamCIS has conducted 255 clinical trials in Phase I to IV, and over 480 projects in Pharmacovigilance and Post-Marketing Surveillance.

About Qualitix Clinical Research
Qualitix Clinical Research Co., Ltd.(http://www.qualitix.com.tw/) Qualitix is a full service CRO based in Taiwan and focuses on clinical monitoring and site management services for multinational phase II and phase III studies. Qualitix was established in June 2008; however, CRO business was commenced since 1997 under its parent company Genovate Biotechnology Co., Ltd. Qualitix plans to establish its presence in China by end of 2009 and expand its service area to China.

About XClinical
XClinical GmbH (www.xclinical.com), an innovative EDC-CDM system vendor based in Munich, Paris and Boston, USA, provides solutions for the electronic conduct of all types of clinical trials, post-marketing studies and registries. 
XClinical develops and markets MARVIN, a CDISC ODM certified online platform for Electronic Data Capture (EDC), Clinical Data Management (CDM) and Clinical Trial Management (CTM). Till today, MARVIN was used to collect and process data of more than 50,000 patients in 50+ studies.

Contact: ASKLEP Corporate Planning and Development Dept. Tel: 81-3-5294-5223

July 7, 2009 – ASKLEP Inc., a full-service CRO with headquarters in Tokyo, will exhibit together with EDC partner XClinical GmbH at the CDISC Japan event. ASKLEP has two projects running in Japan using XClinical’s EDC system MARVIN, in the Japanese language.

XClinical, is a European vendor of innovative software products for eClinical trials, and known for its innovative and user-friendly CDISC ODM certified EDC software suite MARVIN.

ASKLEP and XClinical welcome visitors to drop by their booth during the event to view demonstrations of MARVIN.

In addition to attending as exhibitor, XClinical’s Head of Business Development, Dr. Claus Lindenau will be speaking in the session “CDISC End-To-End”. Within his presentation he will talk about the benefits of using CDISC ODM certified tools to define the CRF structure and the metadata of a CRF. This includes for example the advantages for generating database table definitions and annotated CRF as well as the validation of the CRF structure.

“End-to-end processing – A CDISC ODM metadata-driven 
approach to accelerate CRF design and database set-up”
Dr. Claus Lindenau, XClinical GmbH
Please attend session “CDSIC End to end”
July, 17th , 3:30 p.m. – 4:45 p.m.

About XClinical
XClinical GmbH (www.xclinical.com), an innovative EDC-CDM system vendor based in Munich, Paris and Boston, USA, provides solutions for the electronic conduct of all types of clinical trials, post-marketing studies and registries.
XClinical develops and markets MARVIN, a CDISC ODM certified online platform for Electronic Data Capture (EDC), Clinical Data Management (CDM) and Clinical Trial Management (CTM). Till today, MARVIN was used to collect and process data of more than 50,000 patients in 50+ studies.

About Asklep Inc.
Asklep, Inc., (www.asklep.co.jp) founded in 1992, in Tokyo, Japan, provides clinical research services in monitoring, data management, biostatistics, regulatory & consulting, CRA training, etc. ASKLEP is an INTAGE Group Company. INTAGE, INC., (www.intage.co.jp) is the largest marketing research company in Japan and the eleventh largest globally. It has one of the most comprehensive healthcare solution services in the industry